Deeply experienced technology & life science investor & company builder with a demonstrated track record in transitioning companies and leading them to liquidity events for shareholders, including trade sales, mergers & IPOs.
Mel has over 30 years’ experience building successful, international lifescience, diagnostic and medical device companies and commercialising a wide range of Australian technology. He holds a Bachelor of Science and a Doctorate from the Queensland University of Technology. Mel is also a Fellow of the Australian Institute of Company Directors (AICD) and is also on their Council. Mel is responsible for numerous commercial and M&A transactions and liquidity events exceeding $1 billion. He has raised over $400 million in biotech investment capital.
Mel has received numerous prestigious national and state business awards including the 2005 AusBiotech Chairman’s Industry Medal and 2004 Queensland Entrepreneur of the Year. Mel has successfully founded and exited veterinary and human lifescience companies, including the recent sale of Peptech Animal Health to Virbac in 2011, and Catapult Genetics to Pfizer Animal Health in 2008.
Mel is currently Chair of Anatara Lifesciences (ASX:ANR), director of ASX100 company ALS (ASX:ALQ), and a director of Tissue Therapies Ltd, where he is also the Chair of the Audit & Risk Committee.